| 更新日期 | 產(chǎn)品編號(hào) | 品牌 | 產(chǎn)品信息 | CAS號(hào) | MDL號(hào) | 規(guī)格與純度 | 包裝 | 價(jià)格 | 庫(kù)存信息 | 操作 |
|
2025/05/22
|
HY-W054064
|
|
6-氯-7-脫氮-9-(Β-D-呋喃核糖基)嘌呤
6-Chloro-7-deazapurine-β-D-riboside
|
16754-80-6
|
|
|
25mg
|
246元
|
In-stock
|
詳細(xì)
|
|
2025/05/22
|
HY-W054064
|
|
6-氯-7-脫氮-9-(Β-D-呋喃核糖基)嘌呤
6-Chloro-7-deazapurine-β-D-riboside
|
16754-80-6
|
|
|
50 mg
|
373元
|
In-stock
|
詳細(xì)
|
|
2025/05/22
|
HY-W054064
|
|
6-氯-7-脫氮-9-(Β-D-呋喃核糖基)嘌呤
6-Chloro-7-deazapurine-β-D-riboside
|
16754-80-6
|
|
|
100 mg
|
545元
|
In-stock
|
詳細(xì)
|
|
2025/05/22
|
HY-W054064
|
|
6-氯-7-脫氮-9-(Β-D-呋喃核糖基)嘌呤
6-Chloro-7-deazapurine-β-D-riboside
|
16754-80-6
|
|
|
200 mg
|
803元
|
In-stock
|
詳細(xì)
|
|
2025/05/22
|
XW021675480603
|
|
(2R,3R,4S,5R)-2-(4-氯-7H-吡咯并[2,3-D]嘧啶-7-基)-5-(羥甲基)四氫呋喃-3,4-二醇
|
16754-80-6
|
|
|
1G
|
452元
|
請(qǐng)?jiān)冐浧?
|
詳細(xì)
|
|
2025/05/22
|
XW021675480602
|
|
(2R,3R,4S,5R)-2-(4-氯-7H-吡咯并[2,3-D]嘧啶-7-基)-5-(羥甲基)四氫呋喃-3,4-二醇
|
16754-80-6
|
|
|
250MG
|
114元
|
請(qǐng)?jiān)冐浧?
|
詳細(xì)
|
|
2025/05/22
|
XW021675480601
|
|
(2R,3R,4S,5R)-2-(4-氯-7H-吡咯并[2,3-D]嘧啶-7-基)-5-(羥甲基)四氫呋喃-3,4-二醇
|
16754-80-6
|
|
|
100MG
|
83元
|
請(qǐng)?jiān)冐浧?
|
詳細(xì)
|
|
2024/08/19
|
XW021675480604
|
|
(2R,3R,4S,5R)-2-(4-氯-7H-吡咯并[2,3-D]嘧啶-7-基)-5-(羥甲基)四氫呋喃-3,4-二醇
|
16754-80-6
|
|
|
5G
|
2333元
|
請(qǐng)?jiān)冐浧?
|
詳細(xì)
|